Aveo Pharmaceuticals, INC.: insider trades · United States · SEC (Form 4)

About Aveo Pharmaceuticals, INC.

AVEO PHARMACEUTICALS, INC. is a U.S.-based biopharmaceutical company listed on the NASDAQ in the United States, with a core focus on oncology. Founded in 2001 as GenPath Pharmaceuticals and renamed AVEO Pharmaceuticals in 2005, the company built its strategy around targeted cancer therapies aimed at diseases with significant unmet medical need. Its operating base has long been centered in the Cambridge/Boston, Massachusetts life-sciences cluster, which is consistent with its identity as a development-stage and commercial-stage oncology company. Following its integration into LG Chem’s corporate umbrella, AVEO is now described as an LG Chem company while retaining a distinct oncology franchise and product-development profile. The company’s main business line is the commercialization and life-cycle management of FOTIVDA® (tivozanib), its lead marketed asset. FOTIVDA is an oral, selective VEGF receptor inhibitor approved in the United States for adult patients with relapsed or refractory advanced renal cell carcinoma after at least two prior systemic therapies. This makes AVEO a relatively concentrated oncology biotech with meaningful operating leverage if penetration of the drug improves, if prescribing expands, or if additional evidence supports broader clinical adoption. From a competitive standpoint, AVEO operates in a highly competitive oncology market dominated by large pharmaceutical groups and better-capitalized biotech peers. Its differentiation therefore depends on tivozanib’s selectivity profile, accumulated clinical data, commercial execution, and the ability to generate supporting evidence. Beyond its marketed product, AVEO maintains a development pipeline that includes ficlatuzumab and AV-380/rilogrotug, signaling that the company is still pursuing pipeline optionality rather than relying solely on one asset. Geographically, AVEO remains primarily U.S.-focused, although tivozanib has had an international history and the company benefits from global scientific and corporate links through LG Chem. Recent milestones include the July 2024 announcement that the phase 3 TiNivo-2 study did not meet its primary endpoint, while the company continued presenting tivozanib data at major oncology congresses such as ASCO and ASCO GU in 2025. In January 2026, AVEO announced first patient dosing in a phase 1b/2 AML combination study of ficlatuzumab, underscoring its effort to broaden the pipeline. For French-speaking investors, AVEO is best viewed as a U.S. NASDAQ-listed oncology specialist with a narrow commercial base, a U.S.-centric footprint, and continuing clinical development optionality.